OBJECTIVES: To describe patterns of, and factors associated with, statin use and discontinuation in nursing home (NH) residents progressing to advanced dementia and followed for at least 90 days. DESIGN: Retrospective inception cohort using a dataset linking 2007 to 2008 Minimum Data Set (MDS) to Medicare denominator and Part D files. SETTING: All NHs in five states (Minnesota, Massachusetts, Pennsylvania, California, Florida). PARTICIPANTS: NH residents with dementia. MEASUREMENTS: Residents who developed advanced dementia were observed from baseline (date of progression to very severe cognitive impairment with eating problems) and followed for at least 90 days to statin discontinuation or death. Logistic regression was used to identify baseline factors associated with statin use. Cox proportional hazard regression was used to identify factors associated with time to statin discontinuation. RESULTS: Of 10,212 residents, 16.6% (n = 1,699) used statins. Greater odds of statin use were associated with having diabetes mellitus (adjusted odds ratio (AOR) = 1.24, 95% confidence interval (CI) = 1.09-1.40), stroke (AOR = 1.31, 95% CI = 1.16-1.48), and hypertension (AOR = 1.35, 95% CI = 1.18-1.54); hospice enrollment was associated with lower odds (AOR = 0.75, 95% CI = 0.64-0.89). In follow-up, 37.2% (n = 632) discontinued statins. Median time to discontinuation was 36 days (interquartile range 12-110 days). Shorter time to discontinuation was associated with hospitalization in past 30 days (adjusted hazard ratio (AHR) = 1.67, 95% CI = 1.40-1.99) and more daily medications (AHR = 1.02, 95% CI = 1.01-1.04). When statins were discontinued, 15.0% (n = 95) of residents stopped only statins, and 47.5% (n = 300) stopped at least one other medication. CONCLUSION: Most NH residents who use statins at the time of progression to advanced dementia continue use in follow-up.
OBJECTIVES: To describe patterns of, and factors associated with, statin use and discontinuation in nursing home (NH) residents progressing to advanced dementia and followed for at least 90 days. DESIGN: Retrospective inception cohort using a dataset linking 2007 to 2008 Minimum Data Set (MDS) to Medicare denominator and Part D files. SETTING: All NHs in five states (Minnesota, Massachusetts, Pennsylvania, California, Florida). PARTICIPANTS: NH residents with dementia. MEASUREMENTS: Residents who developed advanced dementia were observed from baseline (date of progression to very severe cognitive impairment with eating problems) and followed for at least 90 days to statin discontinuation or death. Logistic regression was used to identify baseline factors associated with statin use. Cox proportional hazard regression was used to identify factors associated with time to statin discontinuation. RESULTS: Of 10,212 residents, 16.6% (n = 1,699) used statins. Greater odds of statin use were associated with having diabetes mellitus (adjusted odds ratio (AOR) = 1.24, 95% confidence interval (CI) = 1.09-1.40), stroke (AOR = 1.31, 95% CI = 1.16-1.48), and hypertension (AOR = 1.35, 95% CI = 1.18-1.54); hospice enrollment was associated with lower odds (AOR = 0.75, 95% CI = 0.64-0.89). In follow-up, 37.2% (n = 632) discontinued statins. Median time to discontinuation was 36 days (interquartile range 12-110 days). Shorter time to discontinuation was associated with hospitalization in past 30 days (adjusted hazard ratio (AHR) = 1.67, 95% CI = 1.40-1.99) and more daily medications (AHR = 1.02, 95% CI = 1.01-1.04). When statins were discontinued, 15.0% (n = 95) of residents stopped only statins, and 47.5% (n = 300) stopped at least one other medication. CONCLUSION: Most NH residents who use statins at the time of progression to advanced dementia continue use in follow-up.
Authors: Gary Epstein-Lubow; Brandon Gaudiano; Ellen Darling; Mathew Hinckley; Geoffrey Tremont; Robert Kohn; Louis J Marino; Stephen Salloway; Renée Grinnell; Ivan W Miller Journal: Am J Geriatr Psychiatry Date: 2012-09 Impact factor: 4.105
Authors: Holly M Holmes; Greg A Sachs; Joseph W Shega; Gavin W Hougham; Deon Cox Hayley; William Dale Journal: J Am Geriatr Soc Date: 2008-05-12 Impact factor: 5.562
Authors: Susan L Mitchell; Joan M Teno; Dan K Kiely; Michele L Shaffer; Richard N Jones; Holly G Prigerson; Ladislav Volicer; Jane L Givens; Mary Beth Hamel Journal: N Engl J Med Date: 2009-10-15 Impact factor: 91.245
Authors: Michael A Campitelli; Colleen J Maxwell; Laura C Maclagan; Dennis T Ko; Chaim M Bell; Lianne Jeffs; Andrew M Morris; Kate L Lapane; Nick Daneman; Susan E Bronskill Journal: CMAJ Date: 2019-01-14 Impact factor: 8.262
Authors: Joshua D Niznik; Jacob N Hunnicutt; Xinhua Zhao; Maria K Mor; Florentina Sileanu; Sherrie L Aspinall; Sydney P Springer; Mary J Ersek; Walid F Gellad; Loren J Schleiden; Joseph T Hanlon; Joshua M Thorpe; Carolyn T Thorpe Journal: J Am Geriatr Soc Date: 2020-02-17 Impact factor: 5.562
Authors: Carolyn T Thorpe; Florentina E Sileanu; Maria K Mor; Xinhua Zhao; Sherrie Aspinall; Mary Ersek; Sydney Springer; Joshua D Niznik; Michelle Vu; Loren J Schleiden; Walid F Gellad; Jacob Hunnicutt; Joshua M Thorpe; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2020-08-12 Impact factor: 5.562